A5086624484- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Blood disorders and treatments
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Neutropenia and Cancer Infections
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Biological Research and Disease Studies
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Advanced Steganography and Watermarking Techniques
- Machine Learning and ELM
- Quinazolinone synthesis and applications
- Cancer Diagnosis and Treatment
- Synthesis and Biological Activity
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
Jiujiang University
2018-2024
Nanchang University
2012-2023
First Affiliated Hospital of Nanchang University
2015-2023
Weatherford College
2021
Henan University of Science and Technology
2021
Chang'an University
2021
Zhejiang Taizhou Hospital
2018
Wenzhou Medical University
2018
Radiation Oncology Institute
2018
Jiujiang First People's Hospital
2016
The third-generation EGFR-TKIs, such as osimertinib, aumolertinib, and furmonertinib, have been recommended the preferred treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC). Among them, furmonertinib shows several advantages in terms of clinical efficacy. Firstly, compared to osimertinib was first EGFR-TKI with median progression-free survival (mPFS) over 20.0 m (20.8 m) NSCLC classical EGFR-mutations. Furthermore, achieved a mPFS 18.1 unfavorable prognostic factors, 21...
Abstract Objectives Aspirin ( ASA ) has been frequently used for thromboprophylaxis in patients with multiple myeloma MM when treated thalidomide or lenalidomide. Despite the well‐recognized chemopreventive role of some solid tumors particularly colon cancer, whether displays antimyeloma activity remains unclear. Methods MM1.S and RPMI‐8226 cell lines harboring K‐Ras N‐Ras mutation, respectively, were various concentrations different hours. The proliferation apoptosis performed to explore...
Cancer has become an increasingly important public health issue owing to its high morbidity and mortality rates. Although traditional treatment methods are relatively effective, they have limitations such as highly toxic side effects, easy drug resistance, individual variability. Meanwhile, emerging therapies remain limited, their actual anti-tumor effects need be improved. Nanotechnology received considerable attention for development application. In particular, artificial nanocarriers...
Currently, the mechanisms of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance have been a focus clinical research. Despite that most acquired EGFR TKI revealed, about 30% non-small-cell lung cancer (NSCLC) cases not fully elucidated, especially for adenocarcinoma (LUAD). Recently, LPCAT1, an important enzyme phospholipid metabolism, has found to bridge gap between oncogene and metabolic reprogramming. In NSCLC, LPCAT1 shown participate in progression...
Multiple myeloma (MM) was characterized by frequent mutations in KRAS/NRAS/BRAF within the EGFR pathway that could induce resistance to inhibitors. We here report inhibition solely exhibited moderate wildtype (triple-WT) MM cells, whilst had no effect cells with any of mutated genes. The inhibitory conferred induction pentose phosphate (PPP) when were treated Gefitinib, inhibitor. Combination Gefitinib PPP inhibitor 6AN effected synergistically triple-WT cells. be restored addition NADPH....
The histological conversion of lung adenocarcinoma (LUAD) into small-cell cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been recommended as the third-line treatment SCLC patients. efficacy etoposide/platinum (EP) main very limited patients with transformed SCLC. However, little known about EP plus anlotinib present study retrospectively explored clinical response to combined in from...
Nowadays, many traditional approaches which encrypt multimedia data directly are not suitable for the special nature of data. So new encryption have merged to overcome shortcomings and provide confidentiality. But file size increases after encryption. The objective our work is keep JPEG image do affect signal processing JPEG. DC differential residues encrypted through XOR with key that same length stream. DCT blocks scrambled using a key-controlled chaotic map we proposed. information...
Abstract Background Myelodysplastic syndromes (MDS) is a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells. It has been demonstrated that apolipoproteins A1(ApoA1) are associated with disease risk in many cancer types. However, there still lacks evidence regarding the link between ApoA1 and MDS. This study was designed to investigate prognostic value pretreatment levels MDS patients. Methods We retrospectively analyzed cohort 228 patients explore serum...
In our previous study, it was found that aspirin (ASA) exerted antimyeloma actions in vivo and vitro. The resistance to bortezomib (BTZ) multiple myeloma (MM) is partly due AKT activation the upregulation of survivin induced by BTZ, which are targets ASA gastric ovarian cancer, respectively. Thus, present study investigated interaction between BTZ MM further clarified underlying mechanisms. MM1.S RPMI‑8226 cell lines harboring N‑ K‑Ras mutations, respectively, were treated with 2.5 mM ASA,...
Rituximab is a widely used anti‑CD20 monoclonal antibody with high incidence of infusion‑related reactions (IRRs) during administration. Reducing the IRRs remains problematic in hematological practices. In present study, novel strategy prednisone pretreatment regimen was designed similar to combination rituximab, cyclophosphamide, epirubicin, vincristine and (R‑CHOP) aim exploring effect on rituximab patients diffuse large B‑cell lymphoma (DLBCL). A prospective, randomized (1:1) controlled...
Osimertinib, as the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended universally priority front-line therapeutic for advanced non-small cell lung cancer (NSCLC) carrying EGFR-sensitive mutations. However, patients inevitably acquire drug resistance to osimertinib. Aumolertinib is second EGFR-TKI and similarly approved a first-line treatment agent. The present study reports cases of 3 who were challenged with aumolertinib...
α‑fetoprotein (AFP)‑secreting gastric cancer (AFP‑GC) is a relatively rare, aggressive malignancy among all GC types. However, no case with simultaneous expression of AFP and epidermal growth factor receptor 2 (HER2) has been reported to date. To the best our knowledge, present report was first describe use apatinib treat patient advanced characterized by AFP‑secretion HER2‑positivity. An 86‑year‑old man diagnosed AFP‑secretive HER2‑positive liver metastasis at The Affiliated Hospital...
Breast cancer is the most common malignant tumor in women, posing a serious threat to women's health. HER2 has been identified as key oncogene and prognostic factor breast cancer. Recent studies have reported inconsistencies ER, PR, and/or expression between primary tumors metastatic lesions. Rarely it that all three biomarkers experience conversion. In this report, we present case of female patient with relapsed cancer, whose histology transformed from initially triple-negative Luminal-B...
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not high-risk
This study sought to compare the efficacy of prophylactic long-acting and standard granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia, early infections, treatment delay in patients with newly diagnosed multiple myeloma (MM) receiving therapeutic regimen bortezomib, lenalidomide, dexamethasone (VRd).A prospective 68 consecutive MM was conducted three regional hospitals. Participants were randomly treated VRd combination G-CSF (treatment group) or (control group). The primary...
Abstract Known as complementary symmetrical metal oxide semiconductor (cos-mos), is a field effect transistor (MOSFET) manufacturing process, which uses and pairs of p-type n-type MOSFETs to realize logic functions. CMOS technology used build integrated circuit (IC) chips, including microprocessors, microcontrollers, memory chips (including BIOS) other digital circuits. also in analog circuits, such image sensors (CMOS sensors), data converters, RF circuits (RF CMOS), highly transceivers for...
Abstract Objective: The histological conversion of lung adenocarcinoma (LUAD) into small-cell cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been recommended as the third-line treatment SCLC patients. efficacy etoposide/platinum (EP) main very limited patients with transformed SCLC. However, little known about EP plus anlotinib present study retrospectively explored clinical response...
To investigate the expression of pyruvate kinase M2 (PKM2) in bone marrow mesenchymal stem cells (BMSCs) myeloma disease (MBD) and its effect on osteogenic adipogenic differentiation BMSCs.BMSCs were isolated from five patients with multiple (MM) (MM group) iron deficiency anemia (control for culture identification. The PKM2 protein compared between two groups. differences BMSCs assessed by using alkaline phosphatase (ALP) oil red O staining, detecting marker genes osteogenesis adipogenesis....